Barclays Raises its Price Target on CytomX Therapeutics, Inc. (CTMX) to $10 and Maintains an Overweight Rating

Jeff Lewis

Tue, February 17, 2026 at 7:00 PM GMT+9 2 min read

In this article:

CTMX

-2.03%

CytomX Therapeutics, Inc. (NASDAQ:CTMX) is among the 15 Best Small Cap Stocks to Buy According to Wall Street.

Barclays Raises its Price Target on CytomX Therapeutics, Inc. (CTMX) to $10 and Maintains an Overweight Rating

On February 4, 2026, Barclays raised its price target on CytomX Therapeutics, Inc. (NASDAQ:CTMX) to $10 from $8 and maintained an Overweight rating as part of a fourth-quarter earnings preview for the biotechnology group.

Earlier, on January 20, 2026, Piper Sandler lifted its price target to $10 from $6.50 and kept an Overweight rating following initial Phase I data on varsetatug maseatecan. The firm noted that doses of 7.2–10 mg/kg delivered a 28% overall response rate, a 94% disease control rate, and a preliminary median progression-free survival of 5.8 months in third-line and later metastatic colorectal cancer. CytomX is expected to provide an update this quarter on approximately 100 mCRC patients across 7.2 mg/kg, 8.6 mg/kg, and 10 mg/kg q3W expansion cohorts, with Piper anticipating dose-dependent ORR and PFS benefits. Also on January 20, 2026, Guggenheim analyst Michael Schmidt initiated coverage with a Buy rating and a $10 price target, citing what he described as “extraordinary” antitumor activity from Varseta-M in a heavily pre-treated population. The firm’s $10 target reflects 30% odds of success in third-line and later colorectal cancer.

CytomX Therapeutics, Inc. (NASDAQ:CTMX) develops conditionally activated biologics targeting the tumor microenvironment, including antibody-drug conjugates, T-cell engagers, immune modulators, and its PROBODY platform for oncology and preclinical applications.

While we acknowledge the potential of CTMX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Most Profitable Undervalued Stocks to Buy and 11 Best Mining Stocks to Buy According to Wall Street

Disclosure: None.

Terms and Privacy Policy

Privacy Dashboard

More Info